Press ReleaseAbstracts will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 25, 2023
Toronto, Canada, April 5, 2023 — Alpha Cancer Technologies Inc. (ACT) a biopharmaceutical company focused on developing and commercializing targeted immuno-oncology and immunomodulation therapies based on its proprietary recombinant human Alpha Fetoprotein (AFP) platform, today announced that an abstract the company submitted has been accepted by American Society of Clinical Oncology (ASCO) for online publication at the 2023 ASCO Annual Meeting taking place from June 2-6, 2023 in Chicago.
This year, ASCO received and reviewed more than 6,500 abstracts for the 2023 ASCO Annual Meeting. Abstract titles will be posted on April 26, 2023 and abstract text will be released to the public on ASCO’s Meeting Library at 5:00 p.m. ET on May 25, 2023. For more information about the Annual Meeting, please visit: https://conferences.asco.org/am/attend.